Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy
Language English Country Switzerland Media print-electronic
Document type Editorial
PubMed
26508312
DOI
10.1016/j.eururo.2015.10.017
PII: S0302-2838(15)00998-7
Knihovny.cz E-resources
- MeSH
- Anilides therapeutic use MeSH
- Everolimus therapeutic use MeSH
- Carcinoma, Renal Cell drug therapy MeSH
- Humans MeSH
- Antibodies, Monoclonal therapeutic use MeSH
- Kidney Neoplasms drug therapy MeSH
- Treatment Failure MeSH
- Nivolumab MeSH
- Retreatment MeSH
- Antineoplastic Agents therapeutic use MeSH
- Pyridines therapeutic use MeSH
- Practice Guidelines as Topic * MeSH
- Vascular Endothelial Growth Factor A antagonists & inhibitors MeSH
- Check Tag
- Humans MeSH
- Publication type
- Editorial MeSH
- Names of Substances
- Anilides MeSH
- cabozantinib MeSH Browser
- Everolimus MeSH
- Antibodies, Monoclonal MeSH
- Nivolumab MeSH
- Antineoplastic Agents MeSH
- Pyridines MeSH
- Vascular Endothelial Growth Factor A MeSH
The European Association of Urology renal cancer guidelines have been updated to recommend nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of VEGF targeted therapy.
Academic Urology Unit University of Aberdeen Aberdeen UK
Department of Surgical and Perioperative Sciences Urology and Andrology Umeå University Umeå Sweden
Department of Urology and Urologic Oncology Hannover Medical School Hannover Germany
Department of Urology Coimbra University Hospital Coimbra Portugal
Department of Urology Ludwig Maximilians University Munich Germany
Department of Urology Skåne University Hospital Malmö Sweden
Department of Urology Sunderby Hospital Sunderby Sweden
Department of Urology University Hospital Schleswig Holstein Lübeck Germany
Department of Urology University of Rennes Rennes France
Division of Urology Maggiore della Carità Hospital University of Eastern Piedmont Novara Italy
Division of Urology University of Texas Medical School at Houston Houston TX USA
The Royal Free NHS Trust and Barts Cancer Institute Queen Mary University of London London UK
References provided by Crossref.org
International cancer seminars: a focus on kidney cancer
